Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis

D.P. Al-Adra a, R.S. Gill a, S.J. Axford b, X. Shi c, N. Kneteman a, S.-S. Liau d,*

a Department of Surgery, University of Alberta, Edmonton, AB, Canada
b St. George’s University, University Centre, Grenada, West Indies
c Center for the Advancement of Minimally Invasive Surgery, Royal Alexandra Hospital, Edmonton, AB, Canada
d Hepatobiliary Surgical Unit, University Department of Surgery, Addenbrooke’s Hospital, University of Cambridge, United Kingdom

Accepted 22 September 2014
Available online 7 October 2014

Abstract

Radioembolization with yttrium-90 microspheres offers an alternative treatment option for patients with unresectable intrahepatic cholangiocarcinoma (ICC). However, the rarity and heterogeneity of ICC makes it difficult to draw firm conclusions about treatment efficacy. Therefore, the goal of the current study is to systematically review the existing literature surrounding treatment of unresectable ICCs with yttrium-90 microspheres and provide a comprehensive review of the current experience and clinical outcome of this treatment modality. We performed a comprehensive search of electronic databases for ICC treatment and identified 12 studies with relevant data regarding radioembolization therapy with yttrium-90 microspheres. Based on pooled analysis, the overall weighted median survival was 15.5 months. Tumour response based on radiological studies demonstrated a partial response in 28% and stable disease in 54% of patients at three months. Seven patients were able to be downstaged to surgical resection. The complication profile of radioembolization is similar to that of other intra-arterial treatment modalities. Overall survival of patients with ICC after treatment with yttrium-90 microspheres is higher than historical survival rates and shows similar survival to those patients treated with systemic chemotherapy and/or trans-arterial chemoembolization therapy. Therefore, the use of yttrium-90 microspheres should be considered in the list of available treatment options for ICC. However, future randomized trials comparing systemic chemotherapy, TACE and local radiation will be required to identify the optimal treatment modality for unresectable ICC.

Crown Copyright © 2014 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).

Keywords: Cholangiocarcinoma; Radioembolization; Yttrium-90 microsphere

Introduction

Intrahepatic cholangiocarcinoma (ICC) is a malignant transformation of cholangiocytes within the hepatic parenchyma. The incidence of this primary liver malignancy is increasing,1,2 and ICC accounts for up to 15% of primary liver cancers.3 In contrast to the other two locations of cholangiocarcinoma (hilar and distal bile duct), intrahepatic lesions are often asymptomatic and, therefore, present as an incidental mass lesion without jaundice or other stigmata of biliary obstruction.3 Given the asymptomatic nature of many ICCs, patients often present with locally advanced tumours. Although surgery offers the highest curative potential, many tumours are deemed unresectable at the time of diagnosis.5 Patients with unresectable ICC have a median survival of less than eight months.6,7 Systemic chemotherapy with gemcitabine and cisplatin offers an overall survival advantage in patients with advanced biliary cancer8; however, given the aggressive nature of...
cholangiocarcinoma and overall poor prognosis, other treatment modalities are being investigated. Non-selective external beam radiation has higher rates of radiation-induced liver disease as normal hepatic tissue is radiated in addition to the tumour. Recently, yttrium-90 radioembolization for the treatment of hepatocellular carcinoma showed a longer time-to-progression and fewer side-effects than trans-arterial delivered chemotheraphy protocols. In addition, high response rates were seen with radioembolization treatment of intrahepatic neuroendocrine tumours.

Patients with unresectable cholangiocarcinoma have limited treatment options with only modest survival advantages. Local therapy with yttrium-90 microspheres offers the promise of delivering a high dose of radiation directly to the tumour, thereby causing increased tumour destruction. Treatment of ICCs with radioembolization has been attempted; however, only small trials have been performed with this novel treatment. In addition, the relative rarity of ICCs and heterogeneity of this disease makes it difficult to draw firm conclusions about treatment efficacy. The goal of the current study is to systematically review the existing literature surrounding treatment of unresectable ICCs with yttrium-90 microspheres with the aim of providing a comprehensive review of the current experience and clinical outcome of this treatment modality.

Methods

Inclusion criteria for considering studies for this review

Study characteristics

Given the rarity of yttrium-90 radioembolization treatment for unresectable ICC, studies with greater than one patient were included in order to ensure the comprehensive capture of the available clinical experience. This included human case-series (>1 case), randomized controlled trials, non-randomized controlled trials, prospective cohort series.

Participants

The target population consists of adult (>18 years old) male or female patients with unresectable ICC.

Interventions

The intervention under study is radioembolization therapy with yttrium-90 microspheres. The yttrium-90 microsphere treatment may be performed before, synchronously, or after systemic chemotherapy.

Outcome measures

Primary outcomes

The primary outcomes are overall survival and radiological response to radioembolization therapy with yttrium-90 microspheres.

Secondary outcomes

The secondary outcomes of this study are the ability of yttrium-90 treatment to convert unresectable cholangiocarcinoma to resectable, mortality, and morbidity.

Search methods for identification of studies

Electronic searches

Published English-language manuscripts were considered for review with inclusion from 2000 to 2013. A comprehensive search of electronic databases (e.g., MEDLINE, EMBASE, SCOPUS, BIOSIS Previews and the Cochrane Library) using broad search terms was completed. The bibliographies of all included articles were examined to identify additional potentially relevant publications. Search terms included unresectable intrahepatic cholangiocarcinoma, advanced biliary tract cancer, microsphere, SIR-Spheres, Selective Internal Radiation, TheraSphere, yttrium-90, radioembolization and radiation lobectomy.

Data collection and analysis

Selection of studies

All studies involving radioembolization therapy with yttrium-90 microspheres for unresectable ICCs were included. Given the rarity of studies focusing on yttrium-90 microsphere treatment, manuscripts published in abstract form were included. A dedicated search for the full-length manuscripts of published abstracts was also undertaken. A trained librarian conducted the electronic searches (X.S.), and one author (D.A.) conducted a prescreen to identify the articles clearly irrelevant articles by title, abstract and keywords of publication. Following this, three independent reviewers (R.G., S.A. and D.A.) assessed the studies for relevance, inclusion, and methodological quality. Articles were classified as either:

1. Relevant (meeting all specified inclusion criteria);
2. Possibly relevant (meeting some but not all inclusion criteria);
3. Rejected (not relevant to the review).

Three reviewers (R.G., S.A. and D.A.) independently reviewed full-text versions of all studies classified as relevant or possibly relevant. Disagreements were resolved by reextraction, when necessary. In the cases of numerous
publications by the same institution, personal communication with the corresponding authors of those studies was undertaken to ensure the uniqueness of the patients in each study.

Data extraction and management
Two reviewers (D.A. and X.S.) independently extracted data from the full versions of the manuscripts. The extracted information included details of methods (e.g., randomization, blinding, etc.), demographics (e.g., age, sex, etc.), treatment characteristics (e.g. target dose, number of treatments, etc.), clinical characteristics of each group, study inclusion and exclusion criteria, number of patients excluded and lost to follow-up, baseline and post-intervention outcomes (e.g., median survival, etc.), mortality/morbidity data (e.g., death, abdominal pain, length of hospital stay, etc.) and methods of analysis.

Statistical analysis
Pooled analysis was performed on the data from included studies. Descriptive statistics (simple counts, means, and medians) were used to report study, patient- and treatment-level data. The number of patients enrolled was used in the calculation of study and patient demographics. Efficacy outcomes of interest were synthesized by pooling data for patients that underwent therapy involving radioembolization with yttrium-90 microspheres. Due to the high heterogeneity among the studies and lack of randomized controlled trials, a meta-analysis was not deemed appropriate. Statistical calculations were performed using Stata 10 (StataCorp LP, USA) and weighted overall survival and response analysis were performed using Prism 5 (GraphPad Software, San Diego, CA).

Results

Results of the search
A total of 203 articles were identified using our search criteria for screening (Fig. 1). Following assessment by our exclusion criteria, 105 were rejected and 94 studies remained for abstract review. Following abstract review, 50 studies were excluded and 44 studies remained for full-text eligibility assessment. 12 primary studies meeting the inclusion criteria were identified following thorough assessment of the complete manuscripts. These included seven prospective case series and five retrospective cohort studies.

Included studies
11 of the 12 included studies contained median survival data for patients undergoing radioembolization therapy with yttrium-90 microspheres for the treatment of unresectable ICC. Outcome data on mortality, morbidity and complications were available from eight included studies. Baseline characteristics of patients in the included studies are provided in Table 1. A total of 298 patients were assessed in the 12 studies and numbers of patients in each study ranged between 2 and 46. The weighted mean age of the patients was 62.1 years, ranging from 57 to 68. The patients had a median follow-up of 10.8 months (range: 6–29 months).

Characteristics of patients and radioembolization therapy with yttrium-90 microspheres
Details of radioembolization therapy with yttrium-90 microspheres are provided in Table 2. The majority of patients included in the analysis had previously undergone some form of treatment for their ICC prior to radioembolization. Most of these patients previously received chemotherapy (54%) and/or underwent surgical resection (33%). Once patients were deemed refractory to chemotherapy or had unresectable recurrences after initial surgical resection, they were then considered for radioembolization therapy. It was unclear from most studies if chemotherapy was given during or after radioembolization therapy. There was no preference to the type of yttrium-90 delivery system (glass or resin) used to treat the ICC. Based on four included studies, the weighted mean number of treatments per patient was 1.5 with a weighted mean dose of 1.6 GBq.

Primary and secondary outcomes
The primary outcome, survival, was assessed as median survival. Overall weighted median survival was 15.5 months (range: 7–22.2), based on 11 included studies (Table 3). One study did not statistically reach a median survival because data censoring did not allow the survival curve to go below 0.55. However, the mean survival of 17.7 months was close to where the median survival would be should another event occur. Therefore, the nine patients in this study were included in the pooled analysis.

Most commonly, the response evaluation criteria in solid tumours (RECIST) was reported. RECIST is defined as complete response (disappearance of all target lesions), partial response (decrease ≥ 30% in the sum in the greatest dimension of target lesions), stable disease (decrease < 30% or increase < 20% in sum in greatest dimension of target lesions) and progressive disease (increase ≥ 20% in sum in greatest dimension of target lesions and/or progression of non-target lesion). Due to the small number of studies that reported RECIST, these studies were pooled with those reporting the modified (m)RECIST and Positron emission tomography response evaluation criteria in solid tumour (PERCIST; Table 3). Once these studies were pooled, radiological response for solid tumours was reported in six studies. A weighted mean partial response was seen in 28% and stable disease was seen in 54% of patients at three months.

Secondary outcomes included the ability to convert unresectable to resectable disease, mortality, overall
morbidity and type of morbidity (Tables 3 and 4). The ability to offer surgical resection to previously unresectable disease was reported in three studies. Combined, these studies had a total 73 patients, and surgery was performed on seven patients post-radioembolization. Mortality data was specifically reported in three included studies, and of these, there was one treatment-related death. Overall morbidity was reported in eight included studies and is summarized in Table 4. The most common types of morbidity following radioembolization therapy with yttrium-90 microspheres were fatigue (33%), abdominal pain (28%) and nausea (25%).

Discussion

Locally delivered radiation with yttrium-90 microspheres is a novel therapy for patients with unresectable ICC who, otherwise, have limited treatment options. The published experience with radioembolization for the treatment of cholangiocarcinoma is narrow, and of these studies, few document survival outcomes. Furthermore, there are no trials directly comparing the efficacy of yttrium-90 microspheres to other available treatment options, such as systemic chemotherapy or transarterial chemotherapy (TACE). Therefore, in this study, we systematically reviewed the existing literature surrounding treatment of unresectable ICCs with yttrium-90 microspheres.

The primary outcomes of this review are survival and radiological response after treatment with local radiation. The overall median survival of patients with unresectable intrahepatic cholangiocarcinoma is 15.5 months from the initiation of yttrium-90 microsphere therapy. Since there were no randomized comparative trials in this review, it is difficult to compare survival with yttrium-90 microspheres to survival after other treatments. However, recently published data show the overall survival of unresectable ICC after systemic cisplatin-gemcitabine chemotherapy is 11.7 months and survival after treatment with TACE is 13.4 months. All of these results are higher than historical survival times of less than eight months. Taken together, the results of radioembolization are promising as an alternative therapy for patients with unresectable ICC. However, randomized controlled trials will be required to determine the optimal treatment or combination treatment modality.

As with all systematic reviews, the quality of the combined results is dependent on the quality of the original...
articles. For example, the overall survival in our pooled analysis is from a heterogeneous population. Some patients underwent systemic chemotherapy prior to yttrium-90 microsphere treatment and some underwent systemic chemotherapy during treatment, however, we only reported survival since the initiation of the yttrium-90 treatment. Therefore, the overall pooled survival may underestimate the effects of radioembolization if some patients have already undergone previous therapy. One study\textsuperscript{29} highlights this point: the one-year overall survival for patients treated with first-line radioembolization was 84.6\% compared to 20.2\% for those treated with salvage therapy. This study also has the lowest median survival of all included studies.

Selection and publication bias could overestimate the effects of yttrium-90 microspheres treatment, especially in retrospective cohort studies.

Tumour response using RECIST,\textsuperscript{22,25,28} mRECIST\textsuperscript{21} or other radiological criteria\textsuperscript{18,19} was reported in six included studies. In these studies, at three months, partial response was seen in 28\% of patients by imaging criteria and stable

Table 1
Study design and baseline characteristics within included studies for systematic review.

| Reference            | Publication year | Country   | Study interval | Publication type | Study design      | Number of patients | Age (years) | Gender (% male) | Diagnosis       | Liver involved |
|----------------------|------------------|-----------|----------------|------------------|--------------------|--------------------|--------------|-----------------|----------------|----------------|
| Bower and Little et al. | 2013             | Australia | 2002–2012      | Abstract         | Retrospective cohort | 23                 | 62.5         | 48              | ICC            | 10–70%         |
| Camacho et al.        | 2013             | USA       | NA             | Abstract         | Prospective cohort  | 21                 | NA           | NA              | ICC            | NA             |
| Camacho et al.        | 2013             | USA       | NA             | Abstract         | Prospective cohort  | 9                  | 58           | 56              | ICC            | NA             |
| Chaiteerakij et al.   | 2011             | USA       | 2000–2009      | Abstract         | Prospective cohort  | 20                 | NA           | NA              | ICC            | NA             |
| Hoffmann et al.       | 2012             | Germany   | 2007–2010      | Full manuscript  | Prospective cohort  | 33                 | 65.2         | 54.5            | ICC + mets     | <50%           |
| Hyder et al.          | 2013             | USA       | 1992–2012      | Full manuscript  | Retrospective cohort| 46                 | NA           | 48              | ICC + mets     | Tumour >5 cm  |
| Martinez et al.       | 2013             | NA        | 2012           | Abstract         | Prospective cohort  | 2                  | NA           | NA              | ICC            | NA             |
| Mouli et al.          | 2013             | USA       | 2003–2011      | Full manuscript  | Prospective cohort  | 46                 | 68           | 54              | ICC + mets     | <25%           |
| Prajapati et al.      | 2012             | USA       | 2002–2012      | Abstract         | Prospective cohort  | 24                 | NA           | NA              | ICC            | NA             |
| Saxena et al.         | 2010             | Australia | 2004–2009      | Full manuscript  | Prospective cohort  | 25                 | 57           | 52              | ICC + mets     | <50%           |
| Shridhar et al.       | 2012             | USA       | 2009–2011      | Abstract         | Retrospective cohort| 40                 | NA           | NA              | ICC + mets     | NA             |
| Turkmen et al.        | 2013             | Turkey    | 2008–2012      | Full manuscript  | Retrospective cohort| 9                  | NA           | NA              | ICC + mets     | <70%           |

NA, not available; ICC, intrahepatic cholangiocarcinoma; mets, metastatic disease present.

\textsuperscript{a} Mean.

Table 2
Treatment characteristics within included studies.

| Reference            | 90-Yttrium microsphere | Treatments per patient | Dose (GBq) | Other cancer therapy                           |
|----------------------|-------------------------|------------------------|------------|-----------------------------------------------|
| Bower and Little et al. | NA                     | 1.04                   | 0.7–2.19\textsuperscript{b} | Chemotherapy at discretion of oncologist |
| Camacho et al.        | Resin                   | NA                     | NA         | All patients post-chemotherapy (refractory)   |
| Camacho et al.        | Resin                   | NA                     | NA         | All patients post-chemotherapy (refractory)   |
| Chaiteerakij et al.   | Resin                   | 1.55                   | NA         | NA                                            |
| Hoffmann et al.       | Resin                   | 1.03                   | 1.54\textsuperscript{a} | 78.8\% post-chemotherapy, 36.6\% post-surgery |
| Hyder et al.          | NA                      | NA                     | NA         | 27.8\% post-chemotherapy, 11.6\% post-surgery |
| Martinez et al.       | Resin                   | NA                     | NA         | NA                                            |
| Mouli et al.          | Glass                   | 2                      | 3.9 Gy\textsuperscript{c} | 35\% post-chemotherapy, 11\% post-surgery     |
| Prajapati et al.      | Resin                   | NA                     | 1.68\textsuperscript{a} | All patients post-chemotherapy (refractory)   |
| Saxena et al.         | Resin                   | 1.76\textsuperscript{a} | 72\% post-chemotherapy, 40\% post-surgery |
| Shridhar et al.       | Glass                   | NA                     | NA         | 48\% post-chemotherapy, 8\% post-surgery      |
| Turkmen et al.        | Glass and Resin         | NA                     | NA         | All patients post-chemotherapy (refractory)   |

GBq, gigabequerel; NA, not available; Gy, Grey.

\textsuperscript{a} Range.

\textsuperscript{b} Mean.

\textsuperscript{c} Radiation dose reported in Gy, therefore, was not included in weighted analysis.
disease was seen in 54% of patients. Complete responses were only reported in one study where this response was seen in two of nine patients. However, it should be noted that this is also the only study that used positron emission tomography imaging and response evaluation criteria in solid tumours (PERCIST) criteria to evaluate tumour response.

A potential benefit of radiotherapy with yttrium-90 microspheres is the conversion of unresectable to resectable disease. Surgical resection of previously inoperable disease occurred in seven patients in three different studies. In the study by Mouli et al., five patients of their cohort of 46 underwent surgical resection post-treatment with yttrium-90 microspheres. With a median follow-up of over 2.5 years after surgical resection, all five patients were alive. All patients were treatment naïve prior to treatment with yttrium-90 microspheres. Martinez et al. reported one patient who underwent surgical resection post-radioembolization and had no evidence of recurrent or residual disease; however, the length of follow-up was not specified. The positive results of surgical resection in these studies are in accordance with surgical resection offering the highest survival benefit for patients with ICC. Although there is the probability of publication bias, there

### Table 3
Radiological response and survival following treatment with 90-Yttrium microspheres.

| Reference          | Radiology criteria | Response at 3 months (%) | Follow-up* (months) | Survival† (months) | Comments               |
|--------------------|--------------------|--------------------------|---------------------|--------------------|------------------------|
|                    |                    | Complete | Partial | Stable | Progress |                    |                      |
| Bower and Little   | NA                 | NA      | 34.7    | 21.7   | NA       | NA   | 7                   |
| Camacho et al.     | mRECIST            | NA      | NA      | NA     | NA       | NA   | 16.3 (7.2–25.4)     |
| Camacho et al.     | PERCIST            | 22.2    | 33.3    | 33.3   | 11.1     | NA   | 21.7                |
| Chaiteerakij et al.| mRECIST            | 0       | 100°    | 0      | NA       | NA   | 14.6 ± 3.9          |
| Hoffmann et al.    | RECIST             | 0       | 36.4    | 51.5   | 15.2     | 10   | 22                  |
| Hyder et al.       | mRECIST            | 3.1     | 22.4°   | 61.5°  | 13°      | NA   | 11.3                |
| Martinez et al.    | RECIST             | NA      | NA      | NA     | NA       | NA   | 1 downstaged to surgery |
| Mouli et al.       | WHO                | 0       | 25      | 73     | 2        | 29   | 5.3 (n = 10) 14.4 (n = 36) 5 downstaged to surgery |
| Prajapati et al.   | RECIST             | NA      | NA      | NA     | NA       | NA   | 11.5                |
| Saxena et al.      | RECIST             | NA      | 24      | 48     | 20       | 8.1  | 9.3                 |
| Shridhar et al.    | NA                 | NA      | NA      | NA     | 6        | 7.4  | 1 downstaged to surgery |
| Turkmen et al.     | NA                 | NA      | NA      | NA     | NA       | NA   | mean 17.7 ± 3.2     |

NA, not available; (m)RECIST, (modified) response evaluation criteria in solid tumours; PERCIST, PET response evaluation criteria in solid tumours; WHO, World Health Organization.
* Median and range or SE, except where indicated.
† Partial and stable responses were pooled.
‡ Radiological response grouped with other intra-arterial treatment modalities.

### Table 4
Complications following treatment with 90-Yttrium microspheres.

| Reference          | Morbidity (%) | Enzyme increases (%) | Other complications/Comments |
|--------------------|---------------|----------------------|-----------------------------|
|                    | Mortality | Fatigue | Abdominal pain | Fever | Nausea | Jaundice | Bili | AST | Alk Phos |                          |
| Bower and Little   | 0        | 0       | 0              | 0     | 0      | 0          | NA  | NA | NA       |                          |
| Camacho et al.     | NA       | NA      | NA             | NA    | NA     | NA         | NA  | NA | NA       |                          |
| Camacho et al.     | NA       | NA      | NA             | NA    | NA     | NA         | NA  | NA | NA       |                          |
| Chaiteerakij et al.| NA       | 39      | 13             | 0     | NA     | NA         | 35  | NA | 93       |                          |
| Hoffmann et al.    | 0        | NA      | 84.8           | NA    | 60.6   | NA         | 69.7| 54.5| NA       |                          |
| Hyder et al.       | 17       | 12      | 3              | 6     | 2      | NA         | NA  | NA | NA       | Complications grouped with other modes of intra-arterial therapies |
| Martinez et al.    | NA       | NA      | NA             | NA    | NA     | NA         | NA  | NA | NA       | 1 Gastroduodenal ulcer, 2 pleural effusions, 7 ascites |
| Mouli et al.       | NA       | 54      | 28             | NA    | 22     | NA         | 7   | NA | NA       | 1 Duodenal ulcer         |
| Prajapati et al.   | NA       | 17      | 17             | NA    | NA     | NA         | 8.3 | NA | NA       | 1 Duodenal ulcer         |
| Saxena et al.      | 1        | 64      | 40             | NA    | 16     | NA         | 8   | 0  | 4        | 1 Pulmonary Embolism, 4 ascites, 2 pleural effusion |
| Shridhar et al.    | NA       | 15      | 8              | NA    | NA     | 5          | NA  | NA | NA       | 2 Acute radiation hepatitis, 1 chronic radiation hepatitis |
| Turkmen et al.     | NA       | NA      | NA             | NA    | NA     | NA         | NA  | NA | NA       |                          |

NA, not available; bili, bilirubin; AST, aspartate transaminase; Alk Phos, alkaline phosphatase.
is the ability of treatment with yttrium-90 microspheres to downsize tumours to resectability in a minority of patients. Therefore, a potential indication for radioembolization therapy is in cases of borderline resectable tumours at initial presentation.

The overall morbidity and mortality of patients undergoing radioembolization therapy was reported in eight of the 12 included studies (Table 4). Only one death was reported in all of the included studies. Serious morbidity requiring intervention or long-term sequelae included complications of ulcers (due to bead migration), pleural effusions and ascites. The majority of morbidity was from fever, abdominal pain and nausea. Overall, the complication profile of radioembolization is similar to that of chemoembolization seen in recent systematic reviews of similar disease process.

Radioembolization-induced liver disease (jaundice and ascites appearing 1–2 months after radioembolization in the absence of tumour progression or bile duct occlusion) was not specifically mentioned in any study. However, a number of studies did report cases of ascites and hepatitis post-radioembolization, which may indicate radioembolization-induced liver damage did occur. This disease is especially common in radioembolization therapy patients who have previously undergone systemic chemotherapy (which the majority of patients in this review have). Recently, modified radioembolization protocols have been designed to decrease the risk of liver damage post-radioembolization and it is recommended that systemic chemotherapy be delayed by two months.

There are some limitations to the current study. First, five studies were retrospective cohorts which carry the possibility of selection bias. Second, seven included studies were published in abstract form only. Due to their concise nature, abstract publications provide only limited information regarding treatment, follow-up and outcomes. In addition, abstract publications may have not undergone the same stringent peer-review process that a full manuscript has. A dedicated search for the full manuscript of the included abstracts was performed, however, none were found. Third, there is heterogeneity between included studies and no standardized reporting of results. Differences across studies include the type of yttrium-90 radiation microspheres, radiation doses and the length of time of the cohort study. In addition, and likely due to the relative rarity of unresectable ICC, the population within studies is also dissimilar. This heterogeneity includes both patient factors (presence of metastatic disease and size of tumour) and treatment factors (prior chemotherapy or surgical intervention and concomitant chemotherapy). Last, although the search for studies to include in the pooled analysis was stringent, it is possible that some relevant studies were missed.

The pooled analysis of radioembolization therapy with yttrium-90 microspheres for the treatment of unresectable ICC in this study demonstrates an overall survival of 15.5 months. This is higher than historical survival and is similar to survival with systemic chemotherapy and TACE therapy. There is the potential for tumour resectability post-local radiation therapy and the side effect profile is also similar to that seen with TACE therapy for the same disease. Therefore, the use of yttrium-90 microspheres should be considered in the list of available treatment options for ICC. However, future randomized trials comparing systemic chemotherapy, TACE and local radiation will be required to identify the optimal treatment modality for unresectable cholangiocarcinoma. In addition, the creation of a treatment registry with standardized criteria has been recommended by the Brachytherapy Oncology Consortium. Report standardization may also allow any synergistic effects from the concomitant use of chemotherapy and Yttrium-90 radiation microspheres to be identified.

Disclosures

The authors of this manuscript have no conflicts of interest to disclose and there has been no financial support for this research study. DPA, RG and SA participated in study design, performance of research, data analysis and writing the paper. XS and NK participated in performance of research and data analysis. SL participated in study conception, design, data analysis and writing the paper. All authors contributed to critical review of the final manuscript.

Conflict of interest

The authors of this manuscript have no conflicts of interest to disclose and there has been no financial support for this research study. DPA, RG and SA participated in study design, performance of research, data analysis and writing the paper. XS and NK participated in performance of research and data analysis. SL participated in study conception, design, data analysis and writing the paper. All authors contributed to critical review of the final manuscript.

Acknowledgement

S-S Liau is in receipt of the MRC Clinician Scientist Fellowship. He is also funded by University of Cambridge Parke-Davis Fellowship, Royal Society of Medicine Ellison-Cliffe Fellowship, Dowager Countess Eleanor Peel Fellowship, HCA International Foundation Fellowship, European Society of Surgical Oncology Minor Fellowship, and MRC Centenary Early Career Award.

References

1. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004 Mar;40(3):472–7.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001 Jun; 33(6):1353–7.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005 Jan-Feb;55(1):10–30.

4. Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010 Aug;90(4):817–37.

5. Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma—a population-based study. Ann Surg Oncol 2008 Feb;15(2):600–8.

6. Roayae S, Guerrera JV, Ye MQ, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. J Am Coll Surg 1998 Oct;187(4):365–72.

7. Chou FF, Sheen-Chen SM, Chen YS, Chen MC, Chen CL. Surgical treatment of cholangiocarcinoma. Hepatogastroenterology 1997 May-Jun;44(15):780–5.

8. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010 Apr 8;362(14):1273–81.

9. Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethanol, and polyvinyl alcohol: a 2-center study. Cancer 2011 Apr 1;117(7):1498–505.

10. Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization of unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008 Oct 1;113(7):1614–22.

11. Ben-Josef E, Normolle D, Ensmingder WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable hepatic malignancies. J Clin Oncol 2005 Dec 1;23(34):8739–47.

12. Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol 2006 Oct;17(10):1571–93.

13. Riaz A, Kulik LM, Mulcahy MF, Lewandowski RJ, Salem R. Yttrium-90 radioembolization in the management of liver malignancies. Semin Oncol 2010 Apr;37(2):94–101.

14. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011 Feb;140(2):497–507.e2.

15. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010 Jan;138(1):52–64.

16. Kennedy A, Coldwell D, Sangor B, Wasan H, Salem R. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol 2012 Aug;35(4):393–8.

17. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008 Jun;31(3):271–9.

18. Bower G, Little A. Experience with selective internal radiotherapy for patients with intrahepatic cholangiocarcinoma. Intern Med J April 2013;43(5).

19. Camacho JC, Kokabi N, Schuster DM, Kim HS. PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotery: a proof of concept study. J Clin Oncol 20 May 2013;31(15 Suppl. 1).

20. Camacho JC, Kakabi N, Prajapati HJ, El-Rays B, Kim HS. Modified necrict criteria responses at an early time point by contrast enhanced imaging predicts survival in patients with unresectable intrahepatic cholangiocarcinoma (ICC) refractory to standard chemotherapy following intra-arterial yttrium-90 (Y-90) resin-based radioembolization. J Vasc Interv Radiol May 2013;24(5):759.e14–5.

21. Chaiterakaj R, Schmitt GD, Mettler TA, et al. Comparison of transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) for the treatment of unresectable hepatic cholangiocarcinoma. Gastroenterology 2011 May;140(5):S920–1.

22. Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012 Feb;35(1):105–16.

23. Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013 Nov;20(12):3779–86.

24. Martinez BK, Flanders V, Gupta NK, Natarajan K, Underhill MP, Cooke J. Development of a Y90 radioembolization program in a community hospital setting for treatment of metastatic and primary liver tumors. J Vasc Interv Radiol May 2013;24(5):759.e32–3.

25. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013 Aug;24(8):1227–34.

26. Prajapati HJ, Lawal TO, McIntosh EB, El-Rays BF, Kauh JS, Kim HS. Yttrium-90 radioembolization for chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC): survivals and prognostic factors. J Vasc Interv Radiol June 2012;23(6):853.e17–8.

27. Turkmen C, Ucar A, Poyanli A, et al. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm 2013 Sep;28(7):534–40.

28. Saxena A, Bester L, Chua TC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010 Feb;17(2):484–91.

29. Shridhar R, Sweeney J, Biebel B, Hoffe SE, Choi J, Arslan B. Short-term outcomes of intrahepatic cholangiocarcinoma treated with glass based yttrium 90 microspheres. J Vasc Interv Radiol March 2012;23(3 Suppl. 1):S84–5. Conference: 57th Annual Scientific Meeting of the Society of Interventional Radiology 2012 San Francisco, CA United States.

30. Ray CE, Edwards A, Smith MT, et al. Metaanalysis of survival, complications, and imaging response following chemotherapym-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol August 2013;24(8):1218–26.

31. Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases—a systematic review. Surg Oncol 2012 Dec;21(4):299–308.

32. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013 Mar;57(3):1078–87.

33. Kennedy A, Nig S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007 May 1;68(1):13–23.